AU744846B2 - Therapeutic method for management of diabetes mellitus - Google Patents

Therapeutic method for management of diabetes mellitus Download PDF

Info

Publication number
AU744846B2
AU744846B2 AU68899/98A AU6889998A AU744846B2 AU 744846 B2 AU744846 B2 AU 744846B2 AU 68899/98 A AU68899/98 A AU 68899/98A AU 6889998 A AU6889998 A AU 6889998A AU 744846 B2 AU744846 B2 AU 744846B2
Authority
AU
Australia
Prior art keywords
insulin
mammal
tetracycline
agent
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68899/98A
Other languages
English (en)
Other versions
AU6889998A (en
Inventor
Lorne M. Golub
Thomas F. Mcnamara
Nungavaram S. Ramamurthy
Maria Emanuel Ryan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU6889998A publication Critical patent/AU6889998A/en
Application granted granted Critical
Publication of AU744846B2 publication Critical patent/AU744846B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68899/98A 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus Ceased AU744846B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/880,945 US5929055A (en) 1997-06-23 1997-06-23 Therapeutic method for management of diabetes mellitus
US08/880945 1997-06-23
PCT/US1998/006927 WO1998058658A1 (en) 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus

Publications (2)

Publication Number Publication Date
AU6889998A AU6889998A (en) 1999-01-04
AU744846B2 true AU744846B2 (en) 2002-03-07

Family

ID=25377455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68899/98A Ceased AU744846B2 (en) 1997-06-23 1998-04-08 Therapeutic method for management of diabetes mellitus

Country Status (9)

Country Link
US (1) US5929055A (enExample)
EP (1) EP1017414A4 (enExample)
JP (1) JP2002511864A (enExample)
KR (1) KR20010020497A (enExample)
AU (1) AU744846B2 (enExample)
CA (1) CA2294169A1 (enExample)
IL (1) IL133643A0 (enExample)
MX (1) MXPA99011821A (enExample)
WO (1) WO1998058658A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
CA2343038A1 (en) * 1998-09-28 2000-04-06 Maria Emanuel Ryan A novel inhibitor of cataract formation
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
WO2002072146A2 (en) * 2001-03-12 2002-09-19 Novartis Ag Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US20040115261A1 (en) * 2001-04-05 2004-06-17 Ashley Robert A. Controlled delivery of tetracycline compounds and tetracycline derivatives
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
ES2275889T3 (es) * 2001-06-20 2007-06-16 Merck Sante Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante.
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
WO2003059253A2 (en) * 2001-12-21 2003-07-24 Smithkline Beecham Corporation Compositions and methods for altering glucose production
EP2311796A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
WO2003075857A2 (en) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
EA200401232A1 (ru) 2002-03-21 2005-12-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
KR101089429B1 (ko) 2002-07-12 2011-12-07 파라테크 파마슈티컬스, 인크. 3, 10, 및 12ａ 치환된 테트라시클린 화합물
WO2004091483A2 (en) 2003-04-07 2004-10-28 Shire Laboratories, Inc. Once daily formulations of tetracyclines
KR101228706B1 (ko) 2003-07-09 2013-02-01 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
EP1656341A1 (en) 2003-07-09 2006-05-17 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
EP1716101A1 (en) * 2004-01-15 2006-11-02 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2616224A1 (en) * 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
US20070098763A1 (en) * 2005-10-11 2007-05-03 Sinnott Robert A Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
CA2673486C (en) * 2006-12-21 2015-09-08 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
EP3045449A1 (en) 2006-12-21 2016-07-20 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2008134048A2 (en) * 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
EA201070048A1 (ru) * 2007-07-06 2010-10-29 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
PL3000805T3 (pl) 2008-08-08 2018-04-30 Tetraphase Pharmaceuticals, Inc. C7-fluoro podstawione związki tetracyklinowe
ES2627772T3 (es) 2009-05-08 2017-07-31 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina
WO2011025982A2 (en) 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
ES2621409T3 (es) 2010-03-31 2017-07-04 Tetraphase Pharmaceuticals, Inc. Compuestos policíclicos de tetraciclina
AU2013308504B2 (en) 2012-08-31 2016-11-10 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
KR102880712B1 (ko) 2016-10-19 2025-11-03 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
WO2021207487A1 (en) * 2020-04-08 2021-10-14 Hoffman Technologies Llc Methods of treating conditions characterized by insulin deficiency in animals
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013805A1 (en) * 1993-11-17 1995-05-26 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005036A1 (en) * 1984-04-30 1985-11-21 The Trustees Of Columbia University In The City Of Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532227A (en) * 1992-11-17 1996-07-02 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes
WO1995013805A1 (en) * 1993-11-17 1995-05-26 Duke University Medical Center Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF

Also Published As

Publication number Publication date
EP1017414A4 (en) 2004-10-06
WO1998058658A1 (en) 1998-12-30
JP2002511864A (ja) 2002-04-16
US5929055A (en) 1999-07-27
AU6889998A (en) 1999-01-04
CA2294169A1 (en) 1998-12-30
KR20010020497A (ko) 2001-03-15
MXPA99011821A (es) 2002-07-02
IL133643A0 (en) 2001-04-30
EP1017414A1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
AU744846B2 (en) Therapeutic method for management of diabetes mellitus
KR100769786B1 (ko) 메트포르민 및 글리벤클아미드의 복합을 포함하는 제약조성물
AU741215B2 (en) Sulfonylurea-glitazone synergistic combinations for diabetes
US6498193B2 (en) Treatment for complications of type 2 diabetes
US6015803A (en) Antibiotic treatment of age-related macular degeneration
EP1097710B1 (en) Combination product for treating niddm
EP1514550A2 (en) Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
CA2389928A1 (en) Method for treating diabetes
JP2003519621A5 (enExample)
Hanefeld et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
US20240100127A1 (en) Tirzepatide therapeutic methods
Kadhe et al. Advances in drug delivery of oral hypoglycemic agents
US20040176457A1 (en) Novel NIDDM regimen
US20130184350A1 (en) Novel NIDDM Regimen
Wilmshurst, EG & Twigg Which insulin? Which oral hypoglycaemic?
ZA200305225B (en) Spaced drug delivery system.
Gordon The person with type 2 diabetes 4
Diet et al. Incidence and Prevalence Data Base Treatment Report

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)